CA2504280A1 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents
Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Download PDFInfo
- Publication number
- CA2504280A1 CA2504280A1 CA002504280A CA2504280A CA2504280A1 CA 2504280 A1 CA2504280 A1 CA 2504280A1 CA 002504280 A CA002504280 A CA 002504280A CA 2504280 A CA2504280 A CA 2504280A CA 2504280 A1 CA2504280 A1 CA 2504280A1
- Authority
- CA
- Canada
- Prior art keywords
- epa
- dha
- content
- mixture
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000004626 essential fatty acids Nutrition 0.000 title claims abstract 7
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract 6
- 208000020401 Depressive disease Diseases 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 200000000007 Arterial disease Diseases 0.000 title 1
- 208000028922 artery disease Diseases 0.000 title 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract 30
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 29
- 239000000203 mixture Substances 0.000 claims abstract 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 7
- 210000004351 coronary vessel Anatomy 0.000 claims abstract 5
- 208000019553 vascular disease Diseases 0.000 claims abstract 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract 4
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 claims 30
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 2
- 125000004494 ethyl ester group Chemical group 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 229940013317 fish oils Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention concerns the use of a pharmaceutical composition containing essential fatty acid ethyl esters originating from fish oils, in particular as a high concentration mixture of ethyl esters of (20:5.omega. 3) eicosapentaenoic acid (EPA) and (22:6.omega. 3) docosahexaenoic acid (DHA) in the prevention and/or treatment of depression in patients with cardiovascular disease, such as coronary heart and/or coronary artery or vascular disease.
Claims (32)
1. A method for preventing and/or treating depression in patients with cardiovascular disease comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a high content in eicosapentanoic acid ethyl ester (EPA), in docosahexaenoic acid ethyl ester (DHA) or in a high concentration mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA).
2. The method of claim 1 wherein the cardiovascular disease is coronary heart and/or coronary artery or vascular disease.
3. The method of claim 2 wherein the cardiovascular disease is coronary artery or vascular disease.
4. The method of any one of claims 1-3 wherein the essential fatty acids contain a high concentration mixture of EPA and DHA.
5. The method of any one of claims 1-3 wherein the essential fatty acids contain a high content in EPA or in DHA.
6. The method of claim 4 wherein the content in EPA and DHA in such mixture is at least 20% b.w.
7. The method of claim 4 wherein the content in EPA and DHA in such mixture is at least 25% b.w.
8. A method according to claim 4, wherein the content in EPA and DHA in such mixture is from about 30 to about 100% b.w.
9. A method according to claim 4 wherein the content in EPA and DHA in such mixture is from about 30 to about 85% b.w.
10. A method according to any one of claims 4, 6-9, wherein the medicament is administered orally.
11. A method according to claim 10, wherein the medicament is administered orally at a dosage from about 0.7 g to about 6 g daily.
12. A method according to claim 11, wherein the EPA/DHA ratio by weight in the EPA and DHA mixture is about 0.9 to 1.5.
13. The method of claim 5 wherein the content in EPA or DHA is at least 20%
b.w.
b.w.
14. The method of claim 5 wherein the content in EPA or DHA is at least 25%
b.w.
b.w.
15. The method of claim 5 wherein the content in EPA or DHA is from about 60-100% b.w.
16. The method of any one of claims 5, 13-15 wherein the content in EPA or DHA
is administered orally.
is administered orally.
17. A use of a therapeutically effective amount of a medicament containing a high content in EPA, in DHA or in a high concentration mixture of EPA and DHA and a pharmaceutically acceptable vehicle for the treatment of depression in patients with cardiovascular disease.
18. The use of claim 17 wherein the cardiovascular disease is coronary heart and/or coronary artery or vascular disease.
19. The use of claim 18 wherein the cardiovascular disease is coronary artery or vascular disease.
20. The use of any one of claims 17-19 wherein the essential fatty acids contain a high concentration mixture of EPA and DHA.
21. The use of any one of claims 17-19 wherein the essential fatty acids contain a high content in EPA or in DHA.
22. The use of claim 20 wherein the content in EPA and DHA in such mixture is at least 20%
b.w.
b.w.
23. The use of claim 20 wherein the content in EPA and DHA in such mixture is at least 25%
b.w.
b.w.
24. A use according to claim 20, wherein the content in EPA and DHA in such mixture is from about 30 to about 100% b.w.
25. A use according to claim 20 wherein the content in EPA and DHA in such mixture is from about 30 to about 85% b.w.
26. A use according to any one of claims 20, 22-25, wherein the medicament is administered orally.
27. A use according to claim 26, wherein the medicament is administered orally at a dosage from about 0.7 g to about 6 g daily.
28. A use according to claim 27, wherein the EPA/DHA ratio by weight in the EPA and DHA
mixture is about 0.9 to 1.5.
mixture is about 0.9 to 1.5.
29. The use of claim 21 wherein the content in EPA or DHA is at least 20% b.w.
30. The use of claim 21 wherein the content in EPA or DHA is at least 25% b.w.
31. The use of claim 21 wherein the content in EPA or DHA is from about 60-100% b.w.
32. The use of any one of claims 21, 29-31 wherein the content in EPA or DHA
is administered orally.
is administered orally.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101578 | 2004-04-16 | ||
| EPEP04101578.5 | 2004-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2504280A1 true CA2504280A1 (en) | 2005-10-16 |
Family
ID=34928968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002504280A Abandoned CA2504280A1 (en) | 2004-04-16 | 2005-04-15 | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1765319A1 (en) |
| JP (1) | JP2007532605A (en) |
| CN (1) | CN1942180A (en) |
| AU (1) | AU2005244483B2 (en) |
| BR (1) | BRPI0509878A (en) |
| CA (1) | CA2504280A1 (en) |
| IL (1) | IL178300A0 (en) |
| MX (1) | MX291518B (en) |
| RU (1) | RU2387448C2 (en) |
| UA (1) | UA94693C2 (en) |
| WO (1) | WO2005110393A1 (en) |
| ZA (1) | ZA200607794B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| ITMI20100961A1 (en) * | 2010-05-27 | 2011-11-28 | Erredue Spa | MIXTURES RICH IN OMEGA-3 FATTY ACIDS, THEIR COMPOSITIONS AND THEIR PREPARATION PROCESS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048788A1 (en) * | 1997-04-29 | 1998-11-05 | Scotia Holdings Plc | Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants |
| WO2002096408A1 (en) * | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
-
2005
- 2005-04-15 BR BRPI0509878-5A patent/BRPI0509878A/en not_active IP Right Cessation
- 2005-04-15 JP JP2007507767A patent/JP2007532605A/en active Pending
- 2005-04-15 CN CNA2005800114285A patent/CN1942180A/en active Pending
- 2005-04-15 AU AU2005244483A patent/AU2005244483B2/en not_active Ceased
- 2005-04-15 WO PCT/EP2005/004031 patent/WO2005110393A1/en active Application Filing
- 2005-04-15 MX MXPA06011940 patent/MX291518B/en active IP Right Grant
- 2005-04-15 EP EP05779398A patent/EP1765319A1/en not_active Withdrawn
- 2005-04-15 ZA ZA200607794A patent/ZA200607794B/en unknown
- 2005-04-15 RU RU2006140277/14A patent/RU2387448C2/en not_active IP Right Cessation
- 2005-04-15 CA CA002504280A patent/CA2504280A1/en not_active Abandoned
- 2005-04-15 UA UAA200611798A patent/UA94693C2/en unknown
-
2006
- 2006-09-26 IL IL178300A patent/IL178300A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005110393A1 (en) | 2005-11-24 |
| AU2005244483B2 (en) | 2011-06-09 |
| AU2005244483A1 (en) | 2005-11-24 |
| IL178300A0 (en) | 2007-02-11 |
| ZA200607794B (en) | 2008-05-28 |
| MX291518B (en) | 2011-10-31 |
| MXPA06011940A (en) | 2006-12-15 |
| EP1765319A1 (en) | 2007-03-28 |
| BRPI0509878A (en) | 2007-10-16 |
| JP2007532605A (en) | 2007-11-15 |
| CN1942180A (en) | 2007-04-04 |
| RU2387448C2 (en) | 2010-04-27 |
| RU2006140277A (en) | 2008-05-27 |
| UA94693C2 (en) | 2011-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1198608C (en) | Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides | |
| KR100657642B1 (en) | Oil comprising eicosapentaenoic acid and/or stearidonic acid | |
| CA1261274A (en) | Pharmaceutical and dietary compositions | |
| KR101336756B1 (en) | Composition for prevention of recurrence of stroke | |
| JP2020128412A5 (en) | ||
| KR20070098954A (en) | A pharmaceutical composition containing essential fatty acids in the prevention of cardiovascular events | |
| JP2006519244A (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
| WO2010038796A1 (en) | Therapeutic agent for hepatitis c | |
| KR20040004652A (en) | Coenzyme q and eicosapentaenoic acid (epa) | |
| NZ248422A (en) | Use of(dihomo-)gamma-linolenic acid (dgla,gla) or linoleic acid(la) to increase gut calcium absorption in humans | |
| JPH0232017A (en) | Essential fatty acid composition and it production | |
| WO2009091538A8 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| WO2012112531A1 (en) | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases | |
| EP0517425A1 (en) | Fatty acids for the reduction of urinary calcium excretion and the treatment of osteoporosis | |
| CA1287297C (en) | Iron - containing compositions and method for treatment of cancer | |
| CN1126564C (en) | Use of phospholipid complexes of extracts of i(vitis vinifera) as anti-atherosclerotic agent | |
| IE54558B1 (en) | Pharmaceutical composition | |
| EP0257081A1 (en) | Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein | |
| CA2504280A1 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| WO2014095628A1 (en) | Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa) | |
| MX2011001419A (en) | Long-term treatment of symptomatic heart failure. | |
| Eritsland et al. | Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile | |
| JPH0399011A (en) | Pharmaceutical composition | |
| EP2675442A1 (en) | Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events | |
| JP5952556B2 (en) | Pressure ulcer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20141014 |
|
| FZDE | Discontinued |
Effective date: 20141014 |